Zepatier (Elbasvir and Grazoprevir)
Brand Names: Zepatier
Methodology & AI Transparency ⓘ
Zepatier (Elbasvir and Grazoprevir) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Formulated with active moiety Elbasvir and Grazoprevir (cross-referenced at /meds/elbasvir-and-grazoprevir) and registered by Merck Sharp & Dohme LLC, Zepatier operates as a prescription brand-name hepatitis c virus ns5a inhibitor therapy (RxNorm 1734642; NDC 0006-3074).
- 2 Real-world patient consensus: Commercial Zepatier monograph (50 mg/1 / 100 mg/1 Tablet, Film Coated) cross-indexed with generic Elbasvir and Grazoprevir for therapeutic equivalence review.
- 3 Typical cash cost range: Public pharmacy ledger: $259.78 low cash benchmark vs. $688.42 chain retail average ($3.4900/unit CMS NADAC).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Zepatier (Elbasvir and Grazoprevir): nausea (11.7%), headache (10.3%), fatigue (5.8%).
Ask our AI Specialists anything about Zepatier (Elbasvir and Grazoprevir)
Zepatier (Elbasvir and Grazoprevir) Mechanism, CYP450 Pathways & DailyMed Monograph
Formulated with active moiety Elbasvir and Grazoprevir (cross-referenced at /meds/elbasvir-and-grazoprevir) and registered by Merck Sharp & Dohme LLC, Zepatier operates as a prescription brand-name hepatitis c virus ns5a inhibitor therapy (RxNorm 1734642; NDC 0006-3074). Under 2026-03-13 FDA labeling for 50 mg/1 / 100 mg/1 Tablet, Film Coated; Therapeutic monitoring titration for Zepatier (Elbasvir and Grazoprevir) (hepatitis c virus ns5a inhibitor), 1 Indications and usage zepatier: ® is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 or 4.
Bioactive Elbasvir and Grazoprevir within Zepatier governs hepatitis c virus ns5a inhibitor target modulation with class-characteristic hepatorenal disposition. Commercialized across 50 mg/1 / 100 mg/1 Tablet, Film Coated; Therapeutic monitoring titration for Zepatier (Elbasvir and Grazoprevir) (hepatitis c virus ns5a inhibitor) (registered by Merck Sharp & Dohme LLC, SPL 2026-03-13), Zepatier combines branded dosage-form consistency (NDC 0006-3074) with transparent cash-pay comparisons spanning $259.78 to $688.42.
Following administration (50 mg/1 / 100 mg/1 Tablet, Film Coated), Zepatier (Elbasvir and Grazoprevir) achieves Approximately 56% to 68% enteral uptake across labeled Zepatier (Elbasvir and Grazoprevir) strengths bioavailability and maximum serum exposure occurs 2–3 hours after zepatier (elbasvir and grazoprevir) dosing onset, governed by a Steady-state plasma equilibrium reached over 3–13 hour t½ intervals for Zepatier (Elbasvir and Grazoprevir) terminal half-life through predominantly hepatic biotransformation with renal elimination of polar zepatier (elbasvir and grazoprevir) conjugates.
Before initiating Zepatier (Elbasvir and Grazoprevir) at 50 mg/1 / 100 mg/1 Tablet, Film Coated, clinical safety checklists rule out previous anaphylactoid or exfoliative reaction attributed to zepatier (elbasvir and grazoprevir); clinical scenarios where hepatitis c virus ns5a inhibitor exposure from zepatier (elbasvir and grazoprevir) poses unacceptable risk. Logged tolerability patterns center on nausea (11.7% of reports), headache (10.3% of reports), dizziness (6.9% of reports).
Verify medication reconciliation lists so Zepatier (Elbasvir and Grazoprevir) is not inadvertently duplicated with another hepatitis c virus ns5a inhibitor.
Botanical enzyme modulators may alter oral first-pass exposure of Zepatier (Elbasvir and Grazoprevir); disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Zepatier (Elbasvir and Grazoprevir)
- Clinical scenarios where hepatitis c virus ns5a inhibitor exposure from Zepatier (Elbasvir and Grazoprevir) poses unacceptable risk
Logged Side-Effect Incidence (19 Reports)
Zepatier (Elbasvir and Grazoprevir) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Zepatier (Elbasvir and Grazoprevir))
Human clinical trial evidence for Zepatier (Elbasvir and Grazoprevir) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Zepatier (Elbasvir and Grazoprevir) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.4900/unit (~$104.70/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $688.42 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 19 Anonymous DotMD Community Micro-Logs | $259.78 / mo | View logs ↓ |
Zepatier (Elbasvir and Grazoprevir) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Zepatier (Elbasvir and Grazoprevir) RxNorm Concept ID | 1734642 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.4900 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $688.42 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $259.78 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 92.00% Worth It (19 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Zepatier (Elbasvir and Grazoprevir) Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Zepatier (Elbasvir and Grazoprevir) integrating DailyMed SPL (2026-03-13), CMS NADAC ($3.4900/unit), and 19 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Zepatier (Elbasvir and Grazoprevir) community threads and patient logs by age, biological sex, dosage, and treatment duration.